| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 8-K: Other Events |
| 06 Nov 2026 |
8-K: Other Events
Cooley llp 10265 Science Center Drive San Diego, CA 92121t: (858) 550-6000 f: (858) 550-6420 cooley.com |
| 06 Nov 2026 | 424B5 |
| 06 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Reached alignment with FDA on proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint; study-related activities initiated. |
| 04 Nov 2026 | SCHEDULE 13G/A |
| 27 Oct 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
aTyr Pharma, Inc. (the “Corporation”), a corporation organized and existing under the laws of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: |
| 16 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 16, 2026, aTyr Pharma, Inc. (the “Company”) held its 2026 Special Meeting of Stockholders (the “Special Meeting”). As of September 4, 2026, the record date for the Special Meeting (the “Record Date”), 98,087,425 shares of the ... |
| 07 Oct 2026 | SCHEDULE 13G/A |
| 01 Oct 2026 |
Form 4: Yaras Brandon, Chief Financial Officer
Granted 410,000 Employee Stock Option (right to buy) |
| 01 Oct 2026 | Form 3: Yaras Brandon, Chief Financial Officer |
| 24 Sep 2026 |
8-K: Other Events
On September 24, 2026, aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patien... |
| 11 Sep 2026 | DEF 14A |
| 31 Aug 2026 | PRE 14A |
| 07 Aug 2026 | S-8 |
| 07 Aug 2026 | 10-Q |
| 07 Aug 2026 |
8-K: Results of Operations and Financial Condition
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 31 Jul 2026 |
8-K: Termination of a Material Definitive Agreement
This TERMINATION AGREEMENT (this “Agreement”) is made and entered into as of July 30, 2026 (“Execution Date”), by and between aTyr Pharma, Inc., a Delaware corporation, having its principal place of business at 10240 Sorrento Valley Road... |
| 27 Jul 2026 | SCHEDULE 13G/A |
Loading...